ADMA Biologics (NASDAQ:ADMA) Trading Down 6%

ADMA Biologics, Inc. (NASDAQ:ADMA) dropped 6% during trading on Monday . The stock traded as low as $12.32 and last traded at $12.37. Approximately 2,748,320 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 2,878,045 shares. The stock had previously closed at $13.16.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several recent analyst reports. Raymond James lifted their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. Mizuho lifted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. HC Wainwright lifted their price objective on ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald lifted their price objective on ADMA Biologics from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.25.

ADMA Biologics Price Performance

The company has a fifty day moving average price of $11.20 and a two-hundred day moving average price of $7.87. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -618.50 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. The business had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. ADMA Biologics’s quarterly revenue was up 43.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.03) EPS. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CEO Adam S. Grossman sold 100,000 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $10.72, for a total value of $1,072,000.00. Following the sale, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently bought and sold shares of the business. LSV Asset Management acquired a new position in ADMA Biologics in the first quarter worth $1,028,000. BNP Paribas Financial Markets boosted its stake in ADMA Biologics by 152.2% in the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after purchasing an additional 442,315 shares in the last quarter. Alberta Investment Management Corp boosted its stake in ADMA Biologics by 32.4% in the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after purchasing an additional 112,831 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in ADMA Biologics by 90.7% in the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after purchasing an additional 556,175 shares in the last quarter. Finally, Inspire Investing LLC raised its position in shares of ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock worth $1,249,000 after acquiring an additional 105,256 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.